Marc Doble is vice president and general manager for Amgen’s Biosimilars business unit. He is responsible for Amgen’s biosimilars strategy, pipeline, and commercial portfolio.

Prior to this role, Doble was vice president of Operations Transformation and Digital Strategy. Previously, Doble was vice president of Operations Product Advancement, where he led Operations commercialization activities enabling the advancement of Amgen’s pipeline and lifecycle management of Amgen’s commercial products. Doble was also Global Product General Manager for Amgen’s Prolia and EVENITY products, and has served in multiple roles across Operations and corporate functions.

He began his career as a research scientist at Harvard Medical School and worked in product development for start-up biotech companies.

Doble holds a chemistry degree from Holy Cross College and a masters in business and bioscience from Keck Graduate Institute.